We value your privacy

We use cookies to analyze site usage and improve your experience. You can accept all, reject non-essential, or customize. See our Privacy Policy.

Benefits · 8 min read

ERISA basics for employer weight-management programs

By Kevin Wolfe, Founder & CEO

Reviewed by Kindr Health Clinical Team

Published · Updated

Plain-English ERISA questions for plan sponsors evaluating a GLP-1 carve-out, formulary benefit or reimbursement arrangement.

ERISA stands for the Employee Retirement Income Security Act. Despite the name, it also sets requirements for many private-sector employee health benefit plans. Whether and how those requirements apply to a weight-management program depends on what the employer actually establishes and administers.

A vendor label such as “wellness,” “carve-out” or “subscription” does not answer the legal question. Benefits counsel needs the contracts, funding flow, eligibility rules and employee communications.

Who is the plan sponsor?

The plan sponsor is generally the entity that establishes or maintains the employee benefit plan, commonly the employer. A vendor, broker, clinician network, health plan and employer can have different roles even when employees see one brand.

Write those roles down. Identify who determines eligibility, who contracts with clinical providers, who bills participants, who handles appeals or complaints and who maintains plan documents. A clear responsibility map is more useful than a diagram made only of product names.

When do wellness-program rules matter?

The Department of Labor’s Health Benefits Advisor asks whether a wellness program is part of a group health plan. Its guidance explains that a program operated separately as an employment policy may be treated differently from one connected to group-health-plan benefits.

Programs that offer rewards can raise additional questions. DOL guidance distinguishes participatory arrangements from health-contingent ones, including activity-only and outcome-based structures. Do not assume that a program is exempt because participation is described as voluntary, and do not assume every educational program has the same requirements.

This is an area for specific legal review, not a checklist to self-certify compliance.

What documents should be reviewed?

Start with the existing group-health-plan documents and formulary. Add the proposed MSA, Order Form and Plan Language, any HRA or account documents, employee notices, privacy terms and contribution policy.

Check that these materials answer the same questions consistently:

  • Who is eligible, and when does participation begin or end?
  • What does the employer pay, and what does the employee pay?
  • Is medication separate, covered or reimbursable?
  • Does the program offer any reward tied to a health outcome or activity?
  • Which party administers claims, appeals, complaints or exceptions?
  • What information can each party receive?

Contradictions between a sales one-pager and signed language should be resolved before enrollment.

How do formulary coverage and carve-outs differ?

Formulary coverage uses the health plan’s drug list and utilization rules. A carve-out separately administers a defined service, but that does not automatically place it outside ERISA or other benefits laws.

KFF’s 2026 employer survey found that 18% of firms with at least 200 workers covered GLP-1 agonists primarily for weight loss in their largest-enrollment plan. Coverage alone does not describe the program’s legal structure. Two employers reporting “coverage” may have very different documents and vendor arrangements.

What is a sensible governance process?

Have benefits counsel map the arrangement before procurement is final. Involve a tax adviser for HSA, FSA or HRA questions and an insurance professional for coverage questions. Ask privacy and security reviewers to examine data flows and vendor access.

Keep dated copies of the final analysis and documents. Assign an owner for regulatory updates and renewal review. This article can help formulate questions, but it cannot determine the status of your program.

Use the employer benefits glossary for plain-English terms and the GLP-1 program governance hub for the intended Kindr boundaries. To review a proposed structure with our team, request an employer proposal.

This article is general education, not legal, tax or insurance advice.

Sources

Menopause weight gain has a cause — and a protocol.

The metabolic slowdown of menopause is driven by estrogen-related insulin resistance, cortisol, and muscle loss. The kindr Metabolic Reset addresses all three.

See the Metabolic Reset →On a GLP-1? Start here →
Prescription weight care → talk to a physician

Medically reviewed by Kindr Health Clinical Team
Last updated: November 15, 2026

Continue across the Kindr entity graph

Related evidence, peptides, and clinical tools on the same topic.

This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Keep reading

Research

Hormone therapy dispensing has more than doubled: what the new JAMA data mean for you

A new JAMA analysis of pharmacy dispensing, as reported by Science News, finds monthly hormone therapy dispensing to women aged 40 to 74 more than doubled since 2023, with growth in transdermal and vaginal estrogen while pills stayed flat, and we look at what that means for planning care

Research

Menopause equity: why so many women still fall through the cracks, and how to get the care you deserve

An AMWA position paper names gaps that still keep people from menopause care: training, screening, coverage, research and stigma. We look at what's changing in state law, a new academic post in British Columbia, and ACOG's guidance, and we offer a practical checklist for getting evaluated.

Research

Menopause care is going mainstream in state law: what's changing on coverage, education and work

Statehouses are moving on menopause coverage, education and work: what Illinois has enacted, what is pending in Pennsylvania, and what to ask your insurer. A federal survey also shows how few symptomatic women ages 40 to 60 currently take a prescription, and we look at how ACOG's new guidance fits in.

Explore your next step

Kindr Care is being updated, and the exact clinical process will depend on the current care pathway.

Explore care options →